Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nova Leap HealthNVLPF 50 EV-to-EBIT is 32.92 as of Jul. 14, 2026. GuruFocus rates NVLPF with a GF Score™ of 50/100 and a GF Value™ of $0.22 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 468 Healthcare Providers & Services companies, Nova Leap Health ranks worse than 79.7% on this metric.
Nova Leap Health (OTCPK:NVLPF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nova Leap Health's Enterprise Value for the quarter that ended in Mar. 2026 was $23.64 Mil.
Nova Leap Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Leap Health EV-to-EBIT Related Terms
Nova Leap Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nova Leap Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Nova Leap Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Leap Health EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nova Leap Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nova Leap Health's EV-to-EBIT falls into.
Nova Leap Health's current Enterprise Value is $24.59 Mil.
Nova Leap Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Leap Health (NVLPF) has a EV-to-EBIT of 32.92 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nova Leap Health and its competitors. According to the industry distribution chart, Nova Leap Health ranks #373 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 79.7%.
Is Nova Leap Health's EV-to-EBIT too high?
Nova Leap Health's current EV-to-EBIT is 32.92. The Healthcare Providers & Services industry median EV-to-EBIT is 15.87. Nova Leap Health's value of 32.92 is 107.5% above this industry median. Based on the distribution chart, Nova Leap Health ranks #373 out of 468 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Nova Leap Health has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nova Leap Health's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nova Leap Health ranks #373 out of 468 companies for EV-to-EBIT. This places Nova Leap Health in the lower half of its industry. The industry median EV-to-EBIT is 15.87. Nova Leap Health's value of 32.92 is 107.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.87, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Leap Health's current EV-to-EBIT of 32.92 is 107.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nova Leap Health and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Leap Health's current EV-to-EBIT is 32.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Leap Health stock overvalued right now?
Based on GuruFocus' analysis, Nova Leap Health (NVLPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.26 — trading 18.2% above its estimated fair value. The current EV-to-EBIT is 32.92 and 107.5% above the Healthcare Providers & Services industry median of 15.87. Nova Leap Health's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nova Leap Health (NVLPF), the current EV-to-EBIT is 32.92 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Leap Health (NVLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Leap Health stock appears to be overvalued.
The current stock price of $0.26 is trading 18.2% above its estimated GF Value™ of $0.22.
GuruFocus considers Nova Leap Health to be Modestly Overvalued.
Key valuation signals for NVLPF:
EV-to-EBIT: 32.92
GF Value™: $0.22 vs. price of $0.26 (18.2% above fair value)
Industry Position: 107.5% above the Healthcare Providers & Services median (#373 of 468)
No single metric tells the full story. See the NVLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Leap Health Corp operates in the healthcare industry. The company is a provider of home and home health care services to clients..The principal business activities of the company and its subsidiaries are to provide skilled and non-medical home care to clients. Its service offerings include meal preparation, housekeeping, transportation, personal care, and medication reminders. Its segments comprise Canadian and U.S. operations. The company derives a majority of its revenue from the United States.
50GF Score
Get the complete analysis for NVLPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVLPF has been successfully added to your 
